Erratum to: Plaque Rupture and Thrombosis: the Value of the Atherosclerotic Rabbit Model in Defining the Mechanism (Curr Atheroscler Rep, (2016), 10.1007/s11883-016-0587-0);Plaque Rupture and Thrombosis: the Value of the Atherosclerotic Rabbit Model in Defining the Mechanism

Current Atherosclerosis Reports

Volumn 18, Issue 6, 2016, Pages

  Abela, Oliver G ^a   Ahsan, Chowdhury H ^a   Alreefi, Fadi ^b   Salehi, Negar ^c   Baig, Imran ^b   Janoudi, Abed ^b   Abela, George S ^b,c  

^a UNIVERSITY OF NEVADA   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Cholesterol crystals; Inflammation; Plaque rupture; Rabbit model

Indexed keywords

ANIMAL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; DISEASE MODEL; HEART INFARCTION; HUMAN; INFLAMMATION; INTIMA; PATHOLOGY; PATHOPHYSIOLOGY; RABBITS AND HARES; RUPTURE, SPONTANEOUS; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; RABBITS; RUPTURE, SPONTANEOUS; THROMBOSIS; TUNICA INTIMA;

EID: 84963780496     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-016-0605-2     Document Type: Erratum

References (80)

1. Ruffer MA. On arterial lesions found in Egyptian mummies (1580 B.C.–525 A.D.). J Pathol Bacteriol. 1911;15:453.
2. Virchow R. Cellular pathology as based upon physiological and pathological histology (translated by Frank Chance from the 2nd German Edition) London: John Churchill, 1860:p.360.
3. Rokitanski C. A manual of pathological anatomy (translated by William Swaine from German). Vol. 1. London: Sydenham Society, 1854:p.97.
4. Stehbens WE. Anitschkow and the cholesterol over-fed rabbit. Cardiovasc Pathol. 1999;8:177–8.
5. Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885–1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997;135:1–7.
6. Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res. 1996;80:19–44.
7. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction causing sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363–73.
8. Constantinides P, Chakravarti RN. Rabbit arterial thrombosis production by systemic procedures. Arch Pathol. 1961;71:197–208.
9. Ross R, Glomset JA. The pathogenesis of atherosclerosis (First of two parts). N Engl J Med. 1976;295:369–77.
10. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med. 1976;295:420–5.
11. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:2311–6.
12. Düwell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind F, et al. NLRP3 Inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature. 2010;464:1357–62. This report demonstrates for the first time the role of cholesterol crystals in triggering the inflammation cascade leading to IL-1β production.
13. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.
14. Janoudi A, Shamoun FE, Kalavakunta JK, Abela GS. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque. Eur Heart J. 2015. doi:10.1093/eurheartj/ehv653. This article summarizes the concept of plaque rupture related to cholesterol crystallization.
15. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors, and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809–13.
16. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J. 2004;25:1077–82.
17. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL rabbit). Incidence and development of atherosclerosis and xanthoma. Atherosclerosis. 1980;36:261–8.
18. Pundziute G, Schuijf JD, Jukema JW, Decramer I, Sarno G, Vanhoenacker PK, et al. Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. Eur Heart J. 2008;29:2373–81.
19. Baumgartner HR, Studer A. Folgen des Geffasskatheterismus am hypercholesterinaemischen Kaninchen. Pathol Microbiol. 1966;29:393–405.
20. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–6.
21. Khadshadurian AK. The inheritance of essential familial hypercholesterolemia. Am J Med. 1964;37:402–7.
22. Brown MS, Goldstein JL. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc Natl Acad Sci U S A. 1979;76:3330–7.
23. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431–8.
24. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–6.
25. Shiomi M, Ito T, Yamada S, Kawashima S, Fan J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol. 2003;23:1239–44.
26. Shiomi M, Ito T. The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe. Atherosclerosis. 2009;207:1–7.
27. Watanabe Y, Ito T, Saeki M, Kuroda M, Tanzawa K, Mochizuki M, et al. Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia. Atherosclerosis. 1981;38:27–31.
28. Watanabe Y, Ito T, Shiomi M, Tsujita Y, Kuroda M, Arai M, et al. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta. 1988;960:294–302.
29. Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1938–44.
30. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103:993–9.
31. Shiomi M, Ito T, Hirouchi Y, Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis. 2001;157:75–84.
32. Haudenschild C, Studer A. Early interactions between blood cells and severely damaged rabbit aorta. Eur J Clin Investig. 1971;2:1–7.
33. Faxon DP, Balelli LA, Sandborn T, Haudenschild C, Valeri R, Ryan TJ. The effect of antiplatelet therapy on platelet accumulartion after experimental angioplasty in the rabbit iliac model. Int J Cardiol. 1992;36:41–7.
34. Block PC, Baughman KL, Pasternak RC, Fallon JT. Transluinal angioplasty: correlation of morphologic and angiographic findings in an experimental model. Circulation. 1980;61:778–85.
35. Sanborn T, Faxon DP, Haudenschild C, Gottsman SB, Ryan TJ. The mechanism of transluminal angioplasty: evidence for formation of aneurysm in experimental atherosclerosis. Circulation. 1983;68:1136–40.
36. Post MJ, Kuntz RE, Borst C. Remodeling after PTCA: from shrinkage to compensatory enlargement. Circulation. 1995;92:2002–3.
37. Abela GS, Normann SJ, Cohen DM, Franzini D, Feldman RL, Crea F, et al. Laser recanalization of occluded atherosclerotic arteries in vivo and in vitro. Circulation. 1985;71:403–11.
38. Sanborn TA, Haudenschild CC, Garber GR, Ryan TJ, Faxon DP. Angiographic and histologic consequences of laser thermal angioplasty: comparison with balloon angioplasty. Circulation. 1987;75:1281–6.
39. Iqbal J, Chamberlain J, Francis S, Gunn J. Role of animal models in coronary stenting. Ann Biomed Eng. 2015. doi:10.1007/s10439-015-1414-4.
40. Waksman R, McEwan P, Moore T, Pakala R, Kolodgie F, Hellinga D. PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression. J Am Coll Cardiol. 2008;52:1024–32.
41. Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation. 1999;100:1215–22.
42. Runge RS, Haber E. Animal models for the study of thrombolysis in vivo. Circulation. 1991;83(suppl IV):IV–IV2.
43. Priyadharsini RP. Animal models to evaluate anti-atherosclerotic drugs. Fundam Clin Pharmacol. 2015;29:329–40.
44. Constantinides P, Booth J, Carlson G. Production of advanced cholesterol atherosclerosis in the rabbit. Arch Pathol. 1960;70:80–92.
45. Abela GS, Picon PD, Friedl SE, Gebara OC, Federman M, Tofler GH, et al. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation. 1995;91:776–84. This describes the modified model of plaque rupture and thrombosis in the atherosclerotic rabbit model.
46. Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P, Cybulsky MI, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation. 1993;88:1788–803.
47. Phinikaridou A, Hallock KJ, Qiao Y, Hamilton JA. A robust rabbit model of human atherosclerosis and atherothrombosis. J Lipid Res. 2009;50:787–97.
48. Johnstone MT, Botnar RM, Perez AS, Stewart R, Quist WC, Hamilton JA, et al. In vivo magnetic resonance imaging of experimental thrombosis in a rabbit model. Arterioscler Thromb Vasc. 2001;21:1556–60.
49. Viereck J, Ruberg FL, Qiao Y, Perez AS, Detwiller K, Johnstone M, et al. MRI of atherothrombosis associated with plaque rupture. Arterioscler Thromb Vasc Biol. 2005;25:240–5.
50. Phinikaridou A, Ruberg FL, Hallock KJ, Qiao Y, Hua N, Viereck J, et al. In vivo detection of vulnerable atherosclerotic plaque by MRI in a rabbit model. Circ Cardiovasc Imaging. 2010;3:323–32.
51. Pham T, Hua N, Phinikaridou A, Killiany R, Hamilton J. Early in vivo discrimination of vulnerable atherosclerotic plaques that disrupt: a serial MRI study. Atherosclerosis. 2016;244:101–7.
52. Hua N, Baik F, Pham T, Phinikaridou A, Giordano N, Friedman B, et al. Identification of high-risk plaques by MRI and fluorescence imaging in a rabbit model of atherothrombosis. PLoS One. 2015;10, e0139833. doi:10.1371/journal.pone.0139833.
53. Li H, El-Dakdouki MH, Zhu DC, Abela GS, Huang X. Synthesis of ß-Cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals. Chem Commun. 2012;48:3385–7.
54. El-Dakdouki MH, El-Boubbou K, Kamat M, Huang R, Abela GS, Kiupel M, et al. CD44 targeting magnetic glyconanoparticles for atherosclerotic plaque imaging. Pharm Res. 2014;31:1426–37.
55. Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS. Non-Invasive detection and localization of vulnerable plaque and arterial thrombosis using CTA/PET. Circulation. 2008;117:2061–70.
56. Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527–35.
57. Patel R, Janoudi A, Vedre A, Aziz K, Tamhane U, Rubinstein J, et al. Plaque rupture and thrombosis is reduced by lowering cholesterol levels and crystallization with ezetimibe and is correlated with FDG-PET. Arterioscler Thromb Vasc Biol. 2007;31:2007–14. This article is critical in demonstrating how cholesterol crystals form very early in atherosclerosis and also develop thrombosis at sites of heavy crystal deposits.
58. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.
59. Abela GS, Aziz K, Vedre A, Pathak D, Talbott JD, DeJong J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009;103:959–68. This is a landmark report of cholesterol crystals perforating the intimal surface at sites of plaque rupture in humans who died with myocardial infarction.
60. Liu L, Gardecki JA, Nadkarni SK, Toussaint JD, Yagi Y, Bouma BE, et al. Imaging the subcellular structure of human coronary atherosclerosis using micro–optical coherence tomography. Nat Med. 2011;17:1010–4.
61. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events: a novel insight into plaque rupture by scanning electron microscopy. Scanning. 2006;28:1–10. This is the initial report demonstrating the how cholesterol crystals perforate fibrous membranes as they grow and also showed the first human case of crystals perforating the intima of the coronary artery.
62. Goldstein JA. Multifocal coronary plaque instability. Prog Cardiovasc Dis. 2002;44:449–54.
63. Abela GS, Eisenberg JD. Plaque disruption and thrombosis: models to evaluate acute cardiovascular events. In: Becker RC, editor. Textbook of coronary thrombosis and thrombolysis. Boston: Kluwer; 1998. p. 207–17.
64. Naghavi M, Libby P, Falk E, Casscells W, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–72.
65. Abela GS, Aziz K. Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis. Clin Cardiol. 2005;28:413–20.
66. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41.
67. Ma H, Aziz KS, Huang R, Abela GS. Arterial wall cholesterol content is a predictor of development and severity of arterial thrombosis. J Thromb Thrombolysis. 2006;22:5–11.
68. Tian J, Ren X, Vergallo R, Xing L, Yu H, Jia H, et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol. 2014;63:2209–16.
69. Katz SS, Shipley GG, Small DM. Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques. J Clin Invest. 1976;58:200–11.
70. Lundberg B. Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis. 1985;56:93–110.
71. Guo W, Morrisett JD, DeBakey ME, Lawrie GM, Hamilton JA. Quantification in situ of crystalline cholesterol and calcium phosphate hydroxyapatite in human atherosclerotic plaques by solid-state magic angle spinning NMR. Arterioscler Thromb Vasc Biol. 2000;20:1630–6.
72. Vedre A, Pathak DR, Crimp M, Lum C, Koochesfahani M, Abela GS. Physical factors that trigger cholesterol crystallization leading to plaque rupture. Atherosclerosis. 2009;203:89–96.
73. Nasiri M, Huang R, Janoudi A, Vanderberg A, Flegler C, Flegler S, et al. Unraveling the role of cholesterol crystals in plaque rupture by altering the method of tissue preparation. Microsc Res Tech. 2015;78:969–74.
74. Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U. Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol. 2011;107:1710–7.
75. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272–8.
76. Fernandez-Jarne E, Martinez-Losa E, Serrano-Martinez M, Prado-Santamaria M, Brugarolas-Brufau C, Martinez-Gonzalez MA. Type of alcoholic beverage and first acute myocardial infarction: a case–control study in a Mediterranean country. Clin Cardiol. 2003;26:313–8.
77. Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012;59:308–14.
78. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–10.
79. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199–207.
80. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597–605.